Novogen appoints new board members and strategic advisor

4 March 2014

Australian biotech company Novogen (ASX: NRT) has announced the appointments of new board members and a strategic advisor to support its transition into a clinical-stage company with a growing US presence and an investor base in the USA and Australia.

Professor Peter Gunning, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, will join the Novogen board of directors as non-executive directors. David Gryska, an industry expert with more than 20 years of experience in management at many of the top US biotechnology companies, will serve as a strategic advisor to the board with a focus on US capital markets and as a US shareholder liaison.

The board appointments are effective from March 3 and reflect the expansion of Novogen in the USA while maintaining ties to the company’s headquarters in Australia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK